{"id":"F2015L01640","name":"Therapeutic Goods (Listing) Notice 2015 (No. 6)","slug":"therapeutic-goods-listing-notice-2015-no-6","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"repealed","isInForce":false,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":93462,"registerId":"commonwealth-F2015L01640-current","compilationNumber":null,"startDate":"2026-04-02","status":"Repealed","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Therapeutic Goods (Listing) Notice 2015 (No. 6)","content":"Therapeutic Goods Act 1989\n\nTherapeutic Goods (Listing) Notice 2015 (No. 6)\n\nI, Mary McDonald, First Assistant Secretary, Medicines Regulation Division of the Regulatory Services Group of the Department of Health, delegate of the Minister for Health for the purposes of subsection 9A(5) of the Therapeutic Goods Act 1989 and acting under that provision, HEREBY:\n\n    revoke Therapeutic Goods Listing Notice 2015 (No.3); and\n\n    2. require the following therapeutic goods to be included in the part of the Australian Register of Therapeutic Goods (the Register) for listed goods:\n\npreparations that contain ‘Polaprezinc’ as a therapeutically active ingredient, subject to the following conditions:\n\n    the preparation is for oral use only; and\n    the preparation contains a recommended daily dose of 34 milligrams or less of zinc; and\n    when the concentration of zinc is more than 25 mg, the label for the preparation complies with the requirements of the Medicines Advisory Statements Specification.\n\nThis Notice commences from the day after it is registered on the Federal Register of Legislative Instruments.\n\nDated this 7 day of October 2015\n\n(Signed by)\n\nMary McDonald\n\nDelegate of the Minister for Health","sortOrder":0}],"analysis":{"kimi_summary":{"_metrics":{"model":"kimi-k2.5","source":"moonshot-batch","completionTokens":1307},"content_quality":"ok","complexity_score":2,"scope_assessment":{"changed":false,"description":"This notice performs the standard administrative function of updating listing conditions for a specific therapeutic ingredient. While it revokes and replaces Notice 2015 (No. 3), this represents a technical amendment rather than an expansion beyond the original regulatory purpose of controlling which Polaprezinc preparations may be listed in the ARTG."},"complexity_factors":["Short, single-purpose instrument (under 300 words)","Only three specific conditions to meet (route of administration, dosage cap, and conditional labeling)","Single active ingredient specified (Polaprezinc)","Simple revocation of one predecessor instrument","No nested definitions or cross-references to other legislation beyond standard commencement"],"plain_english_summary":"This notice replaces the 2015 notice and allows polaprezinc-containing zinc supplements to be listed on the Australian Register of Therapeutic Goods as lower‑risk, over‑the‑counter medicines. It limits products to oral use, caps daily zinc at 34 mg, and requires specific warning labels if zinc exceeds 25 mg. It governs manufacturers/importers and consumers by setting safe dosage and labelling rules for these supplements."}},"importantCases":[],"_links":{"self":"/api/acts/therapeutic-goods-listing-notice-2015-no-6","history":"/api/acts/therapeutic-goods-listing-notice-2015-no-6/history","analysis":"/api/acts/therapeutic-goods-listing-notice-2015-no-6/analysis","conflicts":"/api/acts/therapeutic-goods-listing-notice-2015-no-6/conflicts","importantCases":"/api/acts/therapeutic-goods-listing-notice-2015-no-6/important-cases","documents":"/api/acts/therapeutic-goods-listing-notice-2015-no-6/documents"}}